Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy.
Rheumatology (Oxford)
; 61(4): e90-e92, 2022 04 11.
Article
in English
| MEDLINE | ID: covidwho-1546021
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dermatomyositis
/
COVID-19
Type of study:
Diagnostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Rheumatology (Oxford)
Journal subject:
Rheumatology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS